Profusa
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $1.2m | Debt | |
$2.8m | Early VC | ||
$11.3m | Late VC | ||
$13.2m | Series B | ||
N/A | $7.5m | Grant | |
* | $45.0m | Series C | |
N/A | N/A | - | |
N/A | Convertible | ||
* | N/A | SPAC IPO | |
Total Funding | AUD123m |
Related Content
Recent News about Profusa
EditProfusa is a biotechnology company specializing in the development of biosensors that provide continuous, real-time monitoring of tissue oxygen levels. The company serves healthcare providers and researchers by offering advanced microsensing technology that can detect early signs of diseases such as chronic limb-threatening ischemia and influenza. Operating in the medical technology market, Profusa's business model focuses on the commercialization of its Oxygen Platform and glucose biosensors. The company generates revenue through the sale of these devices and related software solutions. Profusa's technology is particularly valuable for critical care management and remote patient monitoring, making it a key player in the telehealth and medical diagnostics sectors.
Keywords: biosensors, tissue oxygen, real-time monitoring, chronic ischemia, influenza detection, healthcare, telehealth, remote monitoring, medical diagnostics, biotechnology.